Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Larimar Therapeutics, Inc.LRMR · Entity 5634 | Director | May 10, 2022 | May 13, 2022 |
| Obsidian Therapeutics, Inc.OBX · Entity 4898 | Director | August 03, 2026 | August 05, 2026 |
| REVVITY, INC.RVTY · Entity 3382 | Director | May 07, 2026 | May 11, 2026 |
| SYNLOGIC, INC.SYBX · Entity 7801 | Director | January 02, 2024 | January 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Larimar Therapeutics, Inc.
Report date May 10, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.92 · Expires 2032-05-10 | Direct | 8,300 |
Reported balance
After 2022-05-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-10 · Grant · Acquired 8,300 · Balance 8,300 F1: The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.
Obsidian Therapeutics, Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2036-08-02 | Direct | 37,653 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 37,653 · Balance 37,653 F1: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.
REVVITY, INC.
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,293 |
Ending reported balance
After 2026-05-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-07 · Grant · Acquired 1,015 · Balance 27,028 F1: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control. Row 2 · 2026-05-07 · Grant · Acquired 1,265 · Balance 28,293 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.
SYNLOGIC, INC.
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.47 · Expires 2034-01-02 | Direct | 24,923 |
Reported balance
After 2024-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-02 · Grant · Acquired 24,923 · Balance 24,923 F1: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program and 2015 Equity Incentive Award Plan in lieu of the non-employee director board and committee cash retainers of $81,500 in the aggregate. Such options vest in four equal quarterly installments on the last day of each calendar quarter during 2024 provided the Reporting Person continues to provide services to the Issuer. F2: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program and 2015 Equity Incentive Award Plan in lieu of the non-employee director board and committee cash retainers of $81,500 in the aggregate. Such options vest in four equal quarterly installments on the last day of each calendar quarter during 2024 provided the Reporting Person continues to provide services to the Issuer.
F2: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2017 Filed Nov 14, 2017 21:07 UTC | REVVITY, INC. PKI · Entity 3382 | Exercise / conversionNQ Stock Option (right to buy) · Derivative | 7,071 | $0.00 Strike: $27.79 | $0.00 |
DisclosureSEC source: 0000899243-17-026191 · doc4.xml · derivative · entry 3 Barrett Peter · CIK 0001291895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,071 shares Expires 2019-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option became exercisable in three equal annual installments beginning on May 1, 2013, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 13, 2017 Filed Nov 14, 2017 21:07 UTC | REVVITY, INC. PKI · Entity 3382 | SaleCommon Stock | 7,071 | $71.07 | $502,564.25 |
DisclosureSEC source: 0000899243-17-026191 · doc4.xml · nonDerivative · entry 2 Barrett Peter · CIK 0001291895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 F1 · price: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $71.066 to $71.085. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 13, 2017 Filed Nov 14, 2017 21:07 UTC | REVVITY, INC. PKI · Entity 3382 | Exercise / conversionCommon Stock | 7,071 | $27.79 | $196,467.74 |
DisclosureSEC source: 0000899243-17-026191 · doc4.xml · nonDerivative · entry 1 Barrett Peter · CIK 0001291895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2017 Filed Aug 30, 2017 20:08 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 2,857 | $0.00 Strike: $12.07 | $0.00 |
DisclosureSEC source: 0000899243-17-021261 · doc4.xml · derivative · entry 1 Barrett Peter · CIK 0001291895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,857 Underlying: Common Stock · 2,857 shares Expires 2027-08-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in substantially equal installments on each of the first three anniversaries of the Transaction Date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:08 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0000899243-17-017073 · doc4.xml · derivative · entry 1 Barrett Peter · CIK 0001291895 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2027-06-21 F1 · derivative.exercise_date: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 21, 2018 or the date of the 2018 annual meeting of stockholders, subject to the director's continued service on the board of directors. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 20:09 UTC | REVVITY, INC. PKI · Entity 3382 | Exercise / conversionNQ Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.15 | $0.00 |
DisclosureSEC source: 0000899243-17-015145 · doc4.xml · derivative · entry 3 Barrett Peter · CIK 0001291895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option became exercisable in three equal annual installments beginning on February 7, 2013, which was the first anniversary of the date on which the option was granted. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 20:09 UTC | REVVITY, INC. PKI · Entity 3382 | SaleCommon Stock | 10,000 | $63.22 | $632,230.00 |
DisclosureSEC source: 0000899243-17-015145 · doc4.xml · nonDerivative · entry 2 Barrett Peter · CIK 0001291895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 F1 · price: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $63.215 to $63.260. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 20:09 UTC | REVVITY, INC. PKI · Entity 3382 | Exercise / conversionCommon Stock | 10,000 | $26.15 | $261,450.00 |
DisclosureSEC source: 0000899243-17-015145 · doc4.xml · nonDerivative · entry 1 Barrett Peter · CIK 0001291895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2017 Filed May 10, 2017 20:13 UTC | REVVITY, INC. PKI · Entity 3382 | GrantCommon Stock | 1,598 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-012644 · doc4.xml · nonDerivative · entry 2 Barrett Peter · CIK 0001291895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 Read SEC document |
| May 09, 2017 Filed May 10, 2017 20:13 UTC | REVVITY, INC. PKI · Entity 3382 | GrantCommon Stock | 1,204 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-012644 · doc4.xml · nonDerivative · entry 1 Barrett Peter · CIK 0001291895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,602 F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on May 9, 2018, which is the first anniversary of the date on which the grant was made. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 01:10 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 24,864 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0000899243-17-004094 · doc4.xml · derivative · entry 1 Barrett Peter · CIK 0001291895 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,864 Underlying: Common Stock · 24,864 shares Expires 2027-02-13 F1 · derivative.exercise_date: The stock option was issued in lieu of cash fees under the Non-Employee Director Compensation Policy pursuant to a Non-Qualified Stock Option Agreement and shall vest over a period of one year starting January 1, 2017 on a quarterly basis in arrears. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.